Publicacions en què col·labora amb Alicia Rodríguez Gascón (101)
2024
-
Does selective digestive decontamination (SDD) increase antibiotic resistance? Long-term comparison of two intensive care units (with and without SDD) of the same tertiary hospital
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 5, pp. 885-893
-
Gene therapy with lipid nanoparticles for Fabry disease: Leveraging E-selectin for targeted delivery to endothelial cells
Journal of Drug Delivery Science and Technology, Vol. 99
-
Optimizing Antibiotic Therapy for Stenotrophomonas maltophilia Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach
Antibiotics, Vol. 13, Núm. 6
-
Population pharmacokinetics of oral fosfomycin calcium in healthy women
Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 11, pp. 2837-2845
-
Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems
BioDrugs, Vol. 38, Núm. 5, pp. 657-680
-
Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review
Drug Delivery and Translational Research, Vol. 14, Núm. 10, pp. 2615-2628
2023
-
Absorción de fármacos
Fundamentos de farmacología básica y clínica (Editorial Médica Panamericana), pp. 181-198
-
Ceftaroline and Avibactam Removal by Continuous Renal Replacement Therapies: An in vitro Study
Blood Purification, Vol. 52, Núm. 5, pp. 464-473
-
Expression of a conserved sequence of SARS-CoV-2 for panβ-coronavirus vaccine development
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
-
Nanopartículas lipídicas funcionalizadas con GalNAc para suplementación génica: aplicación en la enfermedad de Fabry
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
-
Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease
Pharmaceutics, Vol. 15, Núm. 7
-
Pharmacokinetic/Pharmacodynamic Analysis of Oral Calcium Fosfomycin: Are Urine Levels Sufficient to Ensure Efficacy for Urinary Tract Infections?
Pharmaceutics, Vol. 15, Núm. 4
-
SLNs como sistemas de transfección para el desarrollo deterapias CAR-T ex vivo
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
-
siRNA vectors based on golden lipid nanoparticles for Fabry Disease
XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones
2022
-
Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease
Nanomaterials, Vol. 12, Núm. 14
-
Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study
Journal of Intensive Care, Vol. 10, Núm. 1
-
mRNA delivery technologies: Toward clinical translation
International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 207-293
2021
-
Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: A pharmacokinetic/pharmacodynamic perspective
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 2, pp. 65-71
-
Functionalised SLNs-based nanovectors for gene therapy in Fabry disease: The liver as an α-Galactosidase A factory
RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 46-48
-
Mrna-based nanomedicinal products to address corneal inflammation by interleukin-10 supplementation
Pharmaceutics, Vol. 13, Núm. 9